Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, a move co-CEO Chirag Patel called pivotal in the company's push to become America's top Affordable Medicines company. The deal pairs Kashiv's biologics research and manufacturing with Amneal's commercial reach, giving Amneal an end-to-end presence in biosimilars, a market that could exceed $300 billion in sales over the next decade as biologic patents expire. Amneal reported second-quarter 2026 net revenue of $796 million, up 10% year over year, with net income more than doubling to $58 million and adjusted EBITDA rising 12% to $206 million. The company raised its full-year revenue outlook to $3.10 billion to $3.20 billion, its second upward revision of 2026, and expects a July repricing of its $2.084 billion term loan to save about $12 million annually in interest. To fund the acquisition, Amneal added a $350 million term loan and increased capital expenditure guidance to about $150 million, while setting aside $30 million for integration costs and $36 million for opioid settlements. Hedge fund ownership of Amneal fell from 36 to 23 funds in the latest quarter, yet short interest remains low at 3.88% of float, indicating market uncertainty rather than conviction.

Amneal Pharmaceuticals reported second-quarter revenue of $796.2 million, up 9.9% year on year and beating analyst estimates by 3.6%, while adjusted earnings per share of $0.30 exceeded consensus by 30.3%. The company raised its full-year revenue guidance to $3.15 billion at the midpoint, a 1.6% increase from the prior outlook, and slightly lifted its adjusted EPS guidance to $1.01. Management attributed the strong performance to robust demand for transdermal patches in women's health, uptake of new complex generics, and growth in branded neurology products such as CREXONT and BREKIYA. The pending acquisition of Kashiv Biosciences is expected to establish Amneal as a fully integrated biosimilars player, with plans to launch six commercial biosimilars by next year targeting a market exceeding $14 billion. The company also highlighted upcoming launches of high-value generics like lanreotide and capacity expansion to meet surging demand.

Amneal Pharmaceuticals has received U.S. FDA approval for additional strengths and vial presentations of iohexol injection, expanding its contrast agent portfolio. The approvals cover 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, as well as 300 mg iodine/mL in a 50 mL vial, with a planned launch in the third quarter of 2026. These new presentations complement the company's previously approved 300 mg iodine/mL in 100 mL vials and are the first generic versions referencing OMNIPAQUE across these presentations. Amneal expects its iohexol portfolio to now address the majority of U.S. market demand, which IQVIA estimates at approximately $706 million in annual sales for the 12 months ended May 2026.

Eli Lilly and Regeneron Pharmaceuticals are among seven drug companies selected by the US FDA for its PreCheck Pilot Program, which aims to improve US drug manufacturing capabilities. The program offers earlier FDA engagement and a more predictable regulatory pathway for companies planning to manufacture drugs for the US market. Other selected companies include Amneal Pharmaceutical and Kyowa Kirin.

Zambon and Amneal Pharmaceuticals announced that the CHMP has adopted a positive opinion recommending EU marketing authorization for Hopledo®, a modified-release levodopa/carbidopa treatment for adults with Parkinson’s disease and moderate to severe motor fluctuations. The recommendation is based on the Phase 3 RISE-PD trial, which showed Hopledo® significantly increased “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa. Hopledo® is already approved and marketed in the United States as CREXONT®. If approved by the European Commission, Zambon expects to begin a phased introduction across European markets starting in October 2026. More than one million people are living with Parkinson’s disease in the EU, and over 80% experience motor fluctuations during the course of their disease.